ClinicalTrials.gg
CompletedNCT02025985SIGNUpdated Jan 26, 2023Results posted

Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies

A Phase 2 interventional study of Selinexor in Ovarian Carcinoma, Endometrial Carcinoma and Cervical Carcinoma, sponsored by Karyopharm Therapeutics Inc. Completed at 4 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.

Sponsored by Karyopharm Therapeutics Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies in Ovarian Neoplasms with a site in Denmark — 17 open to participants now, 27 under way, 15 of them phase 3. Ovarian Neoplasms · Denmark.

Enrollment
56th of 90
116 · median 237
Started
2014
with 1 other
Phase 2
21 of 104
3 open now
Registered
39th of 104
by date

Among the 104 studies in Ovarian Neoplasms with a site in Denmark, this one is the 56th largest by enrollment of the 90 interventional ones that give a count, is one of 2 that started in 2014, is one of 21 in phase 2, and was the 39th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

17 of the 104 studies in Ovarian Neoplasms with a site in Denmark are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Ovarian Neoplasms with a site in Denmark, or all of them as a file.
02

Study summary

The primary trial objective is to determine the efficacy of KPT-330 (selinexor) in participants with advanced or metastatic gynaecological cancers by disease control rate (complete response (CR) or partial response (PR) or stable disease (SD) for at least 12 weeks, assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Read the detailed description

Two-stage Phase 2 study in 3 separate gynecological cancer cohorts, with an additional set of participants in the ovarian cohort randomized into 2 different treatment regimens. The study is divided between a Primary Treatment Phase and a Maintenance Phase with each phase supported by a separate database.

Part 1 - Three parallel cohorts of participants with ovarian (Cohort A), endometrial (Cohort B), or cervical (Cohort C) carcinoma were enrolled.

Part 2 - Based on the observed tolerability and efficacy profile in the ongoing ovarian cohort (Cohort A), 2 additional treatment schedules will be explored to optimize the dosing schedule in a participant population with ovarian carcinoma.

03

Conditions studied

  • Ovarian Carcinoma
  • Endometrial Carcinoma
  • Cervical Carcinoma

Keywords

  • Karyopharm
  • KPT-330
  • Selinexor
  • SIGN
  • ovarian cancer
  • endometrial cancer
  • cervical cancer
  • SINE™
  • HER2 negative
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status of 0-1.
  • Adequate hematologic function defined as:

    • ≥125*10\^9 per liter (/L)
    • ≥5.59 millimoles per liter (mmol/L) or 9 grams per deciliter (g/dL)
    • (ANC) ≥1.5*10\^9/L
    • White blood cells (WBC) count ≥3.0*10\^9/L
    • Up to 5 percent (%) deviation is tolerated. Transfusions and growth factors are allowed.
  • Adequate liver function defined as adequate hepatic function within 14 days prior to Cycle 1 Day 1: total \<2 times the (ULN) (except participants with Gilbert's syndrome, who must have a total bilirubin of \<3 times ULN), (AST) \<2.0 times ULN, and alanine aminotransferase (ALT) \<2.0 times ULN. In the case of known (radiologically and/or - documented) liver , AST \<5.0 times ULN and ALT \<5.0 times ULN is acceptable. Up to 10% deviation is acceptable.
  • Renal function defined as a calculated or measured ≥30 milliliter per minute (mL/min).
  • The participant has recovered to Grade less than or equal to (≤) 1 by the National Cancer Institute , Version 4.03 (NCI-CTCAE v4.03) from the effects of recent surgery, radiotherapy, chemotherapy, hormonal therapy, or other targeted therapies, with the exception of alopecia. The exceptions for such effects are allowed lab values of ≤Grade 2 specified elsewhere in these inclusion criteria.
  • of at least 12 weeks.
  • Able to swallow and retain oral medication.
  • Participants must give according to the rules and regulations of the individual participating sites.
  • Negative serum pregnancy test in women of within 14 days of first dose of treatment, and participants of childbearing potential must agree to use effective during treatment up to 3 months from last dose. Fertile male partners must be willing and able to use effective non-hormonal means of contraception (barrier method of contraception in conjunction with spermicidal jelly, or surgical sterilization) during and for at least 6 months post-study treatment.
  • The participant must be recovered from any prior treatment/major operation. The treatment/major operation must be performed at least 4 weeks prior to start of study drug. Palliative radiotherapy is permitted until one week prior to the start of study drug.
  • Only incurable participants with or cytologically proven primary tumor and objective documentation of disease progression on prior treatment by computerized tomography (CT)/ magnetic resonance imaging (MRI) may be enrolled.
  • Ovarian, fallopian tube, or peritoneal carcinoma: both platinum * and platinum resistant** participants, who have received ≥1 for relapsed disease (i.e., ≥2 lines of chemotherapy in total).

    *Platinum refractory is defined as progression during or within 4 weeks of last treatment with a platinum-containing therapy.

    **Platinum resistant is defined as relapse 4 weeks to \<6 months after a platinum-containing therapy.

  • Endometrial carcinoma: participants must have received ≥1 line of chemotherapy for relapsed or advanced (Stage IV, IIIc) disease.
  • Cervical carcinoma: participants must have received ≥1 line of chemotherapy for relapsed or advanced (Stage IV b) disease.
  • Carcinosarcomas (Malignant Mixed Mullerian Tumor) are allowed, but all other nonepithelial cancers of the ovary, fallopian tube, endometrium, or cervix are excluded.
  • Participants must have either per 1.1 or evaluable disease outside irradiated field on CT/MRI. For ovarian cancer: Participants must have disease that is measurable according to RECIST or assessable according to the Gynecological Cancer Intergroup (GCIG) CA-125 criterion. A rise in CA-125 or other tumor marker alone is not sufficient.

Exclusion criteria

Exclusion Criteria:

  • Disease-Specific Exclusions:

    • Evidence of complete or partial bowel obstruction.
    • Need of Total Parenteral Nutrition.
  • Participants who are pregnant or breast feeding.
  • Radiation (except planned or on-going palliative radiation to bone outside of the region of ) ≤3 weeks prior to Cycle 1 Day 1.
  • Chemotherapy, endocrine therapy, immunotherapy or any other systemic anti-cancer therapy (including anti-cancer therapy) ≤3 weeks prior to Cycle 1 Day 1.
  • Diagnosis or recurrence of invasive cancer other than the present cancer within 3 years (except basal or squamous cell carcinoma of the skin that has been definitively treated).
  • Unstable cardiovascular function:

    • Symptomatic ischemia, or
    • Uncontrolled conduction abnormalities (e.g. ventricular tachycardia on anti-arrhythmics are excluded and 1st degree atrioventricular (AV) block or asymptomatic left anterior fascicular block (LAFB)/ right bundle branch block (RBBB) will not be excluded), or
    • Congestive heart failure (CHF) of (NYHA) Class ≥3, or myocardial infarction (MI) within 3 months of Cycle 1 Day 1.
  • Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to the first dose. Active infection with concurrent treatment is acceptable only if the participant is clinically stable.
  • Significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea.
  • Concurrent therapy with approved or investigational anti-cancer therapeutics.
  • Medical, psychological, or social conditions that may interfere with the participant's participation in the study or evaluation of the study results.
  • Known unless adequately treated (surgery or radiotherapy) with no evidence of progression and neurologically stable off anticonvulsants and .
  • All non-epithelial cancers of the ovary, fallopian tube, peritoneum, endometrium or cervix as well as neuro-endocrine tumors are excluded.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    Part 1: Cohort A-Ovarian carcinoma: Selinexor up to 60 mg/m^2 BIW

    Participants with ovarian carcinoma who were platinum refractory or platinum resistant and had received at least one line of chemotherapy for relapsed disease received a dose of 50 milligram per meter square (mg/m\^2) of selinexor oral tablets twice weekly (BIW) (doses at least 36 hours apart) with light meal and 120 milliliters (mL) of water in a 4-week treatment cycles. After 12 weeks of treatment, a dose of 60 mg/m\^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m\^2 once weekly (QW). This treatment continued until progression of disease (PD) or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.

    Drug: Selinexor

  • Experimental
    Part 1: Cohort B-Endometrial carcinoma: Selinexor up to 60 mg/m^2 BIW

    Participants with endometrial carcinoma who had received at least one line of chemotherapy for relapsed or advanced (Stage IVb, IIIc) disease received a dose of 50 mg/m\^2 of selinexor oral tablets BIW (doses at least 36 hours apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 12 weeks of treatment, a dose of 60 mg/m\^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m\^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.

    Drug: Selinexor

  • Experimental
    Part 1: Cohort C-Cervical carcinoma: Selinexor up to 60 mg/m^2 BIW

    Participants with cervical carcinoma who had received at least one line of chemotherapy for relapsed or advanced (Stage IV) disease received a dose of 50 mg/m\^2 of selinexor oral tablets BIW (doses at least 36 hours apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 12 weeks of treatment, a dose of 60 mg/m\^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m\^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.

    Drug: Selinexor

  • Experimental
    Part 2: Cohort A-Ovarian carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW

    Participants with ovarian carcinoma who were platinum refractory or platinum resistant and had received at least one line of chemotherapy for relapsed disease received a dose of 35 mg/m\^2 of selinexor oral tablets BIW (doses at least 36 hours apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 6 weeks of treatment, a dose of 50 mg/m\^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m\^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.

    Drug: Selinexor

  • Experimental
    Part 2: Cohort A-Ovarian carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW

    Participants with ovarian carcinoma who were platinum refractory or platinum resistant and had received at least one line of chemotherapy for relapsed disease received a dose of 50 mg/m\^2 of selinexor oral tablets QW (doses at least 5 days apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 6 weeks of treatment, a dose of 60 mg/m\^2 of selinexor oral tablets QW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m\^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.

    Drug: Selinexor

Interventions

  • Route of administration and dosage form: Oral tablet; Doses: 35 mg/m\^2 BIW, 35 mg/m\^2 QW, 50 mg/m\^2 BIW, 50 mg/m\^2 QW, 60 mg/m\^2 BIW, 60 mg/m\^2 QW. Treatment cycles were 4 weeks each i.e., 28 day cycles.

    Also known as: KPT-330, XPOVIO

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Disease Control Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

    Disease Control Rate (DCR) was defined as the point estimate of the percentage of participants who had complete response (CR), partial response (PR), or stable disease (SD) for at least 12 weeks, assessed according to RECIST v1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Participants without documented disease progression were censored on the date of last radiologic assessment.

    Time frame: Baseline up to 30 days after last dose administration, assessed after 6 weeks and 12 weeks (approximately 35 months)

Secondary outcomes

  1. Percentage of Participants With Overall Response According to RECIST v1.1

    Overall Response Rate (ORR) was defined as the point estimate of the percentage of participants who had CR or PR, assessed according to RECIST v1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Baseline up to the date of progression or recurrence (approximately 35 months)

  2. Percentage of Participants With Disease Control According to Gynecological Cancer Intergroup (GCIG) Response Criteria

    DCR was defined as the point estimate of the percentage of participants who had CR, PR, or SD for at least 12 weeks, assessed according to GCIG response criteria (RECIST v1.1 and CA-125).

    Time frame: Baseline up to 30 days after last dose administration, assessed after 6 weeks and 12 weeks (approximately 35 months)

  3. Percentage of Participants With Overall Response According to GCIG Response Criteria

    ORR was defined as the point estimate of the percentage of participants who had CR or PR, assessed according to GCIG response criteria (RECIST v1.1 and CA-125).

    Time frame: Baseline up to the date of progression or recurrence (approximately 35 months)

  4. Progression-free Survival (PFS) According to RECIST v1.1

    PFS was defined as the time from date of start of study therapy to the date of tumor disease progression (i.e., radiological only) or date of death due to any cause. Participants without documented disease progression were censored at the time of last radiologic assessment. Participants without any post baseline assessments were censored at date of start of study therapy.

    Time frame: From start of study drug administration until PD or discontinuation from the study or death, whichever occurred first (approximately 35 months)

  5. Overall Survival (OS)

    OS was defined as time from the date of start of study therapy to the date of death due to any cause. Participants who were alive at the time of the analysis or were lost to follow-up were censored at the day they were last known to be alive. Kaplan-Maier method was used for estimation.

    Time frame: From start of study treatment up to the date of death, assessed every 3 months (approximately 35 months)

  6. Percentage of Participants Who Survived at 12 and 24 Months

    OS rate was reported as the percentage of participants who were alive at 12 and 24 months. OS was defined as time from the date of start of study therapy to the date of death due to any cause. Participants who were alive at the time of the analysis or are lost to follow-up were censored at the day they were last known to be alive. Survival rate were estimated by Kaplan-Maier method.

    Time frame: 12 and 24 months

  7. Number of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAE) According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03

    An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not it is considered related to the medicinal product. A serious adverse event (SAE) was defined as an AE that meets one or more of the mentioned criteria, i.e., fatal, life threatening (places the participants at immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events. TEAE was defined as any AE (serious/non-serious) with onset or worsening of a pre-existing condition on or after the first administration of study medication through 30 days following last dose or any event considered drug-related by the investigator through the end of the study.

    Time frame: From start of study treatment up to 30 days after the last dose administration (approximately 35 months)

  8. Number of Participants With Treatment-emergent Adverse Events by Severity According to National Cancer Institute Common Terminology Criteria for Adverse Events NCI CTCAE, Version 4.03

    AE: any unfavorable and unintended sign, symptom, or disease temporally associated with use of medicinal product, whether or not it is considered related to medicinal product. TEAE: any AE (serious/non-serious) with onset or worsening of a pre-existing condition on or after the first administration of study drug through 30 days following last dose or any event considered drug-related by investigator through end of study. As per NCI-CTCAE version 4.03, Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE.

    Time frame: From start of study treatment up to 30 days after the last dose administration (approximately 35 months)

  9. Quality of Life (QoL): Change From Baseline European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQC30) Scores

    EORTC QLQC30: Disease specific indication that rates overall QoL in cancer participants. It consists of 30 general questions from 3 domains; 1) global health status, 2) functioning scales (physical, emotional, cognitive, social and role functioning), 3) symptom scales (fatigue, nausea, vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhea, financial difficulty). Out of 30 questions, 28 questions were scored using scale of 1 to 4, represented answers of 'not at all', 'a little', 'quite a bit', and 'very much'; remaining 2 questions contributed to global health status were scored on scale of 1 to 7, represented range of 'very poor' to 'excellent' that evaluated overall health and QoL. All scales and single-item measures range from 0 to 100, where higher score represented higher response level. Higher score for functional scale, global health status and symptom scale represented high level of functioning, high QoL, and high level of symptoms or problems, respectively.

    Time frame: Baseline, End of treatment (EOT) i.e., 30 days after last dose of study drug administration (up to 31 months)

  10. Number of Participants With Individual Clinically Significant Abnormalities in Laboratory Tests

    Clinically significant laboratory tests abnormalities were analyzed and reported for this outcome measure.

    Time frame: From start of study treatment up to 30 days after the last dose administration (approximately 35 months)

07

Results

Posted Feb 2, 2021

Participant flow

The study was conducted between 09-April-2014 and 29-Mar-2017.

Participant flow — Overall Study
MilestonePart 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIWmg/m^2Part 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW
Started2523252120
Modified intent-to-treat(mitt)population2322252120
Completed00000
Not completed2523252120
Withdrew: Consent withdrawn00100
Withdrew: Termination of study by sponsor43113
Withdrew: Death2120232017

Outcome measures

PrimaryPercentage of Participants With Disease Control Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

Disease Control Rate (DCR) was defined as the point estimate of the percentage of participants who had complete response (CR), partial response (PR), or stable disease (SD) for at least 12 weeks, assessed according to RECIST v1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Participants without documented disease progression were censored on the date of last radiologic assessment.

Time frame:
Baseline up to 30 days after last dose administration, assessed after 6 weeks and 12 weeks (approximately 35 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Control Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
percentage of participantsPart 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW
Percentage of Participants With Disease Control Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)30.4 (13.2 to 52.9)36.4 (17.2 to 59.3)24.0 (9.4 to 45.1)33.3 (14.6 to 57.0)30.0 (11.9 to 54.3)
SecondaryPercentage of Participants With Overall Response According to RECIST v1.1

Overall Response Rate (ORR) was defined as the point estimate of the percentage of participants who had CR or PR, assessed according to RECIST v1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Baseline up to the date of progression or recurrence (approximately 35 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Response According to RECIST v1.1
percentage of participantsPart 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW
Percentage of Participants With Overall Response According to RECIST v1.18.7 (1.1 to 28.0)13.6 (2.9 to 34.9)4.0 (0.1 to 20.4)9.5 (1.2 to 30.4)15.0 (3.2 to 37.9)
SecondaryPercentage of Participants With Disease Control According to Gynecological Cancer Intergroup (GCIG) Response Criteria

DCR was defined as the point estimate of the percentage of participants who had CR, PR, or SD for at least 12 weeks, assessed according to GCIG response criteria (RECIST v1.1 and CA-125).

Time frame:
Baseline up to 30 days after last dose administration, assessed after 6 weeks and 12 weeks (approximately 35 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Control According to Gynecological Cancer Intergroup (GCIG) Response Criteria
percentage of participantsPart 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW
Percentage of Participants With Disease Control According to Gynecological Cancer Intergroup (GCIG) Response Criteria16.0 (4.5 to 36.1)23.8 (8.2 to 47.2)20.0 (5.7 to 43.7)
SecondaryPercentage of Participants With Overall Response According to GCIG Response Criteria

ORR was defined as the point estimate of the percentage of participants who had CR or PR, assessed according to GCIG response criteria (RECIST v1.1 and CA-125).

Time frame:
Baseline up to the date of progression or recurrence (approximately 35 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Response According to GCIG Response Criteria
percentage of participantsPart 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW
Percentage of Participants With Overall Response According to GCIG Response Criteria4.0 (0.1 to 20.4)9.5 (1.2 to 30.4)10.0 (1.2 to 31.7)
SecondaryProgression-free Survival (PFS) According to RECIST v1.1

PFS was defined as the time from date of start of study therapy to the date of tumor disease progression (i.e., radiological only) or date of death due to any cause. Participants without documented disease progression were censored at the time of last radiologic assessment. Participants without any post baseline assessments were censored at date of start of study therapy.

Time frame:
From start of study drug administration until PD or discontinuation from the study or death, whichever occurred first (approximately 35 months)
Reported as:
Median · days
Progression-free Survival (PFS) According to RECIST v1.1
daysPart 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW
Progression-free Survival (PFS) According to RECIST v1.179.0 (45.0 to 99.0)86.5 (43.0 to 182.0)44.0 (43.0 to 141.0)85.0 (44.0 to 148.0)44.5 (43.0 to 140.0)
SecondaryOverall Survival (OS)

OS was defined as time from the date of start of study therapy to the date of death due to any cause. Participants who were alive at the time of the analysis or were lost to follow-up were censored at the day they were last known to be alive. Kaplan-Maier method was used for estimation.

Time frame:
From start of study treatment up to the date of death, assessed every 3 months (approximately 35 months)
Reported as:
Median · days
Overall Survival (OS)
daysPart 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW
Overall Survival (OS)172.0 (62.0 to 372.0)226.0 (111.0 to 449.0)152.0 (83.0 to 254.0)348.0 (149.0 to 401.0)173.0 (105.0 to 353.0)
SecondaryPercentage of Participants Who Survived at 12 and 24 Months

OS rate was reported as the percentage of participants who were alive at 12 and 24 months. OS was defined as time from the date of start of study therapy to the date of death due to any cause. Participants who were alive at the time of the analysis or are lost to follow-up were censored at the day they were last known to be alive. Survival rate were estimated by Kaplan-Maier method.

Time frame:
12 and 24 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Survived at 12 and 24 Months
percentage of participantsPart 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW
12 months34.8 (16.6 to 53.7)31.8 (14.2 to 51.1)13.2 (3.4 to 29.9)33.3 (14.9 to 53.1)25.0 (9.1 to 44.9)
24 months21.7 (7.9 to 39.9)13.6 (3.4 to 30.9)4.4 (0.3 to 18.4)19.0 (5.9 to 37.7)15.0 (3.7 to 33.5)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAE) According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03

An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not it is considered related to the medicinal product. A serious adverse event (SAE) was defined as an AE that meets one or more of the mentioned criteria, i.e., fatal, life threatening (places the participants at immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events. TEAE was defined as any AE (serious/non-serious) with onset or worsening of a pre-existing condition on or after the first administration of study medication through 30 days following last dose or any event considered drug-related by the investigator through the end of the study.

Time frame:
From start of study treatment up to 30 days after the last dose administration (approximately 35 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAE) According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03
ParticipantsPart 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW
Participants with TEAE2523252120
Participants with TESAE141461212
SecondaryNumber of Participants With Treatment-emergent Adverse Events by Severity According to National Cancer Institute Common Terminology Criteria for Adverse Events NCI CTCAE, Version 4.03

AE: any unfavorable and unintended sign, symptom, or disease temporally associated with use of medicinal product, whether or not it is considered related to medicinal product. TEAE: any AE (serious/non-serious) with onset or worsening of a pre-existing condition on or after the first administration of study drug through 30 days following last dose or any event considered drug-related by investigator through end of study. As per NCI-CTCAE version 4.03, Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE.

Time frame:
From start of study treatment up to 30 days after the last dose administration (approximately 35 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events by Severity According to National Cancer Institute Common Terminology Criteria for Adverse Events NCI CTCAE, Version 4.03
ParticipantsPart 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW
Mild (Grade 1)00000
Moderate (Grade 2)33557
Severe (Grade 3)1917171513
Life threatening (Grade 4)32210
Fatal (Grade 5)01100
SecondaryQuality of Life (QoL): Change From Baseline European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQC30) Scores

EORTC QLQC30: Disease specific indication that rates overall QoL in cancer participants. It consists of 30 general questions from 3 domains; 1) global health status, 2) functioning scales (physical, emotional, cognitive, social and role functioning), 3) symptom scales (fatigue, nausea, vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhea, financial difficulty). Out of 30 questions, 28 questions were scored using scale of 1 to 4, represented answers of 'not at all', 'a little', 'quite a bit', and 'very much'; remaining 2 questions contributed to global health status were scored on scale of 1 to 7, represented range of 'very poor' to 'excellent' that evaluated overall health and QoL. All scales and single-item measures range from 0 to 100, where higher score represented higher response level. Higher score for functional scale, global health status and symptom scale represented high level of functioning, high QoL, and high level of symptoms or problems, respectively.

Time frame:
Baseline, End of treatment (EOT) i.e., 30 days after last dose of study drug administration (up to 31 months)
Reported as:
Mean · scores on a scale
Quality of Life (QoL): Change From Baseline European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQC30) Scores
scores on a scalePart 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW
Global Health Status/ QoL: Baseline52.8 ± 22.4159.5 ± 20.6360.2 ± 24.2561.5 ± 22.8957.5 ± 21.95
Global Health Status/ QoL: EOT-8.3 ± 11.79-11.4 ± 29.88-14.6 ± 10.49-27.4 ± 31.81-13.9 ± 15.52
Functioning Scales/ Physical Functioning: Baseline69.5 ± 19.1670.9 ± 21.5466.1 ± 26.0267.1 ± 21.1470.7 ± 25.26
Functioning Scales/ Physical Functioning: EOT-26.7 ± 28.28-16.4 ± 27.55-24.2 ± 21.32-7.6 ± 16.97-18.9 ± 14.25
Functioning Scales/ Role Functioning: Baseline54.0 ± 29.7759.5 ± 31.8755.6 ± 35.4959.5 ± 28.6663.3 ± 34.45
Functioning Scales/ Role Functioning: EOT-33.3 ± 47.14-3.0 ± 49.90-20.8 ± 36.96-9.5 ± 39.51-25.0 ± 9.13
Functioning Scales/ Emotional Functioning: Baseline62.3 ± 24.8169.8 ± 24.6571.2 ± 23.8174.2 ± 19.5366.3 ± 23.33
Functioning Scales/ Emotional Functioning: EOT-16.7 ± 11.79-0.8 ± 38.2712.5 ± 14.43-13.9 ± 23.07-2.8 ± 17.21
Functioning Scales/ Cognitive Functioning: Baseline81.0 ± 22.5486.5 ± 16.3583.3 ± 25.2083.3 ± 19.0080.8 ± 23.12
Functioning Scales/ Cognitive Functioning: EOT-33.3 ± 23.57-6.1 ± 29.134.2 ± 20.97-16.7 ± 38.490.0 ± 0.00
Functioning Scales/ Social Functioning: Baseline61.1 ± 29.9776.2 ± 32.3172.7 ± 28.8969.0 ± 30.8677.5 ± 29.75
Functioning Scales/ Social Functioning: EOT-33.3 ± 0.00-6.1 ± 48.46-20.8 ± 20.97-7.1 ± 18.90-30.6 ± 32.35
Symptom Scales/Items/ Fatigue: Baseline46.6 ± 27.8043.4 ± 27.4244.9 ± 27.7546.0 ± 27.2841.7 ± 27.89
Symptom Scales/Items/ Fatigue: EOT33.3 ± 47.146.1 ± 41.091.4 ± 17.2023.8 ± 30.3816.7 ± 11.65
Symptom Scales/Items/ Nausea And Vomiting: Baseline13.5 ± 24.5117.5 ± 30.049.8 ± 15.995.6 ± 14.2710.8 ± 21.81
Symptom Scales/Items/ Nausea And Vomiting: EOT8.3 ± 11.79-0.0 ± 40.8216.7 ± 19.259.5 ± 23.2913.9 ± 16.39
Symptom Scales/Items/ Pain: Baseline34.9 ± 27.8437.3 ± 27.3432.6 ± 27.9331.0 ± 29.4832.5 ± 26.75
Symptom Scales/Items/ Pain: EOT-8.3 ± 11.79-4.5 ± 21.204.2 ± 8.33-2.4 ± 17.822.8 ± 26.70
Symptom Scales/Items/ Dyspnoea: Baseline23.8 ± 31.8730.2 ± 36.3719.7 ± 30.2733.3 ± 38.0121.7 ± 29.17
Symptom Scales/Items/ Dyspnoea: EOT50.0 ± 23.576.1 ± 32.728.3 ± 16.67-0.0 ± 47.1416.7 ± 18.26
Symptom Scales/Items/ Insomnia: Baseline31.7 ± 34.1236.5 ± 31.4630.3 ± 32.3820.6 ± 26.8238.3 ± 29.17
Symptom Scales/Items/ Insomnia: EOT-16.7 ± 23.57-9.1 ± 30.15-16.7 ± 33.33-19.0 ± 26.235.6 ± 32.77
Symptom Scales/Items/ Appetite Loss: Baseline25.4 ± 31.4634.9 ± 32.4530.3 ± 36.9623.8 ± 28.1715.0 ± 27.52
Symptom Scales/Items/ Appetite Loss: EOT16.7 ± 23.570.0 ± 53.7516.7 ± 43.0333.3 ± 47.1416.7 ± 34.96
Symptom Scales/Items/ Constipation: Baseline27.0 ± 27.1215.9 ± 24.9915.2 ± 26.6817.5 ± 30.9511.7 ± 16.31
Symptom Scales/Items/ Constipation: EOT0.0 ± 47.146.7 ± 43.898.3 ± 16.679.5 ± 31.71-5.6 ± 13.61
Symptom Scales/Items/ Diarrhoea: Baseline17.5 ± 30.959.5 ± 26.1318.2 ± 24.6218.3 ± 31.488.3 ± 14.81
Symptom Scales/Items/ Diarrhoea: EOT0.0 ± 0.00-3.0 ± 34.820.0 ± 27.2223.8 ± 25.2027.8 ± 32.77
Symptom Scales/Items/ Financial Difficulties: Baseline7.9 ± 17.974.8 ± 15.9416.7 ± 26.739.5 ± 18.695.0 ± 12.21
Symptom Scales/Items/ Financial Difficulties: EOT16.7 ± 23.573.0 ± 17.980.0 ± 0.004.8 ± 29.99-5.6 ± 13.61
SecondaryNumber of Participants With Individual Clinically Significant Abnormalities in Laboratory Tests

Clinically significant laboratory tests abnormalities were analyzed and reported for this outcome measure.

Time frame:
From start of study treatment up to 30 days after the last dose administration (approximately 35 months)
Reported as:
Count of participants · Participants
Number of Participants With Individual Clinically Significant Abnormalities in Laboratory Tests
ParticipantsPart 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW
Number of Participants With Individual Clinically Significant Abnormalities in Laboratory Tests2120191411

Adverse events

Collected over From start of study treatment up to 30 days after last dose administration (approximately 35 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIW21/25 (84%)14/25 (56%)25/25 (100%)
Part 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIW20/23 (87%)14/23 (60.9%)23/23 (100%)
Part 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIW23/25 (92%)6/25 (24%)25/25 (100%)
Part 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW20/21 (95.2%)12/21 (57.1%)21/21 (100%)
Part 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW17/20 (85%)12/20 (60%)20/20 (100%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventPart 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW
VomitingGastrointestinal disorders5/251/230/250/210/20
AscitesGastrointestinal disorders2/250/230/250/214/20
NauseaGastrointestinal disorders0/251/231/250/212/20
General Physical Health DeteriorationGeneral disorders0/250/230/250/212/20
HyponatraemiaMetabolism and nutrition disorders0/252/230/250/210/20
Deep Vein ThrombosisVascular disorders0/252/230/250/211/20
IleusGastrointestinal disorders2/250/230/251/210/20
DehydrationMetabolism and nutrition disorders2/251/230/251/210/20
HyperglycaemiaMetabolism and nutrition disorders2/251/230/250/210/20
Pleural EffusionRespiratory, thoracic and mediastinal disorders2/250/230/250/211/20
Most frequent other events
Showing 10 of 110
Most frequent other events
EventPart 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW
NauseaGastrointestinal disorders22/2515/2317/2517/2115/20
Decreased AppetiteMetabolism and nutrition disorders12/2518/2312/2516/2110/20
VomitingGastrointestinal disorders18/2514/2311/2513/2112/20
Weight DecreasedInvestigations12/2513/2318/2511/216/20
FatigueGeneral disorders12/2515/2315/2514/2114/20
AnaemiaBlood and lymphatic system disorders13/2511/2314/259/215/20
ConstipationGastrointestinal disorders7/256/236/2511/217/20
ThrombocytopeniaBlood and lymphatic system disorders12/2510/2313/254/211/20
DiarrhoeaGastrointestinal disorders6/257/236/2510/218/20
DysgeusiaNervous system disorders7/255/2311/254/216/20

Baseline characteristics

Baseline analysis was performed on safety population that included all participants who had received any amount of study drug.

Age, Categorical
Age, Categorical(Participants)Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QWTotal
<=18 years000000
Between 18 and 65 years17620131470
>=65 years81758644
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QWTotal
Female2523252120114
Male000000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QWTotal
Hispanic or Latino000000
Not Hispanic or Latino2523252120114
Unknown or Not Reported000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: Cohort A-Ovarian Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort B-Endometrial Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 1: Cohort C-Cervical Carcinoma: Selinexor up to 60 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIWPart 2: Cohort A-Ovarian Carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QWTotal
Race — White2523242120113
Race — Other-unspecified001001
08

Study locations

4 sites
  • UZ Leuven - Universitair Ziekenhuis Leuven
    Leuven, B-3000, Belgium
  • Aalborg University Hospital
    Aalborg, DK-9100, Denmark
  • Rigshospitalet
    Copenhagen, DK-2100, Denmark
  • Herlev Hospital
    Herlev, DK-2730, Denmark
09

References and documents

Publications

  • Vergote IB, Lund B, Peen U, Umajuridze Z, Mau-Sorensen M, Kranich A, Van Nieuwenhuysen E, Haslund C, Nottrup T, Han SN, Concin N, Unger TJ, Chai Y, Au N, Rashal T, Joshi A, Crochiere M, Landesman Y, Shah J, Shacham S, Kauffman M, Mirza MR. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies. Gynecol Oncol. 2020 Feb;156(2):308-314. doi: 10.1016/j.ygyno.2019.11.012. Epub 2019 Dec 9. PubMed 31822399 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in Jan 2017, 33 months.

Results were first posted in Feb 2021, 4 years after primary completion.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 33 months is below that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2013
First posted
Jan 1, 2014
StartActual
Apr 9, 2014
Primary completionActual
Jan 24, 2017
CompletionActual
Mar 29, 2017
Results first posted
Feb 2, 2021
Last update
Jan 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02025985
Responsible party
Sponsor
First posted
Jan 1, 2014
Start date
Apr 9, 2014
Primary completion
Jan 24, 2017
Completion
Mar 29, 2017
Results posted
Feb 2, 2021
Last update
Jan 26, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion